Pharmaceutical - Pharmaceutical, Eli Lilly

Filter

Current filters:

PharmaceuticalEli Lilly

Popular Filters

1 to 25 of 204 results

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

03-03-2015

US drug major Eli Lilly has licensed late-stage neuroscience drug pomaglumetad methionil (mGlu2/3 receptor…

Eli LillyLicensingNeurologicalPharmaceuticalpomaglumetad methionilUSA

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Eli Lilly delays US and Europe filings for new diabetes agent peglispro

23-02-2015

US pharma major Eli Lilly says it is delaying the submission of its basal insulin peglispro (BIL) to…

DiabetesEli LillyEuropepeglisproPharmaceuticalRegulationUSA

Lilly accepts committee recommendation to extend evacetrapib study by six months

Lilly accepts committee recommendation to extend evacetrapib study by six months

20-02-2015

US drug major Eli Lilly has accepted the recommendation of the ACCELERATE study academic executive committee…

Cardio-vascularEli LillyevacetrapibPharmaceuticalResearchUSA

FDA approves Boehringer Ingelheim and Eli Lilly's Glyxambi for type 2 diabetes

FDA approves Boehringer Ingelheim and Eli Lilly's Glyxambi for type 2 diabetes

02-02-2015

The US Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets from German…

Boehringer IngelheimDiabetesEli LillyGlyxambiPharmaceuticalRegulation

Eli Lilly's fourth quarter financials hit by patent expiries and currency issues

Eli Lilly's fourth quarter financials hit by patent expiries and currency issues

30-01-2015

US drugmaker Eli Lilly’s fourth quarter financials were hit by genericization and currency fluctuations,…

CymbaltaEli LillyEvistaFinancialPharmaceutical

FTC puts conditions on Eli Lilly’s proposed acquisition of Novartis Animal Health

23-12-2014

US pharma major Eli Lilly has agreed to divest its Sentinel product line of medications for treating…

Eli LillyMergers & AcquisitionsNovartisPharmaceuticalUSA

Eli Lilly receives marketing authorization from the European Commission for Cyramza

Eli Lilly receives marketing authorization from the European Commission for Cyramza

22-12-2014

Eli Lilly has received marketing authorization from the European Commission for its drug Cyramza.

CyramzaEli LillyOncologyPharmaceuticalUSA

FDA approves third indication for Lilly’s Cyramza

FDA approves third indication for Lilly’s Cyramza

13-12-2014

The US Food and Drug Administration on Friday expanded the approved use of pharma major Eli Lilly’s…

CyramzaEli LillyOncologyPharmaceuticalRegulationUSA

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

12-12-2014

The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society UK announced new funding…

CialisDiabetesEli LillyliraglutideMen's HealthNeurologicalNovo NordiskPharmaceuticalResearchTadalafilVictoza

Patent cliff means pharma will lose $65 billion by 2019, says report

Patent cliff means pharma will lose $65 billion by 2019, says report

11-12-2014

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent…

AbilifyAstraZenecaEli LillyGlobalMarkets & MarketingNeurologicalOtsukaPatentsPharmaceuticalSeroquelZyprexa

World’s largest collection of deprioritized pharma compounds opens to researchers

World’s largest collection of deprioritized pharma compounds opens to researchers

09-12-2014

A collection of 68 deprioritized pharmaceutical compounds is being made available to academic researchers…

AstraZenecaEli LillyGlaxoSmithKlineJanssen Research & DevelopmentPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

02-12-2014

US drug major Eli Lilly and AstraZeneca have enrolled the first patient into AMARANTH, a Phase II/III…

AstraZenecaAZD3293Eli LillyNeurologicalPharmaceuticalResearch

Eli Lilly's Trulicity approved in the EU for type 2 diabetes

Eli Lilly's Trulicity approved in the EU for type 2 diabetes

26-11-2014

US drug major Eli Lilly has received approval from the European Commission for its GLP-1 receptor agonist…

DiabetesEli LillyEuropePharmaceuticalRegulationTrulicity

Added benefit of Jardiance not proven, says IQWiG

19-11-2014

Following an examination as to whether Jardiance (empagliflozin) offers an added benefit over appropriate…

Boehringer IngelheimDiabetesEli LillyGermanyJardiancePharmaceuticalPricingRegulation

Boehringer Ingelheim and Lilly revise diabetes alliance in certain countries

29-10-2014

In a move that will strengthen their 2011 alliance by enhancing efficiencies and enabling greater focus…

Boehringer IngelheimDiabetesEli LillyJardianceJentaduetoLicensingMarkets & MarketingPharmaceuticalTrajenta

Takeda and Lilly’s fine is reduced in Actos case

Takeda and Lilly’s fine is reduced in Actos case

28-10-2014

A US district court has reduced the damages to be paid by Japan’s largest drugmaker Takeda Pharmaceutical…

ActosDiabetesEli LillyLegalPharmaceuticalTakeda PharmaceuticalUSA

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

23-10-2014

US drug major Eli Lilly reported third quarter 2014 results that showed how badly the company has been…

CymbaltaEli LillyEli Lilly and CompanyEvistaFinancialPharmaceuticalUnited StatesUSA

Lilly expands collaboration with Zymeworks

Lilly expands collaboration with Zymeworks

23-10-2014

US pharma major Eli Lilly and privately-held Canadian biotech firm Zymeworks have expanded their existing…

CanadaEli LillyLicensingOncologyPharmaceuticalResearchUSAZymeworks

Three members of Novartis’ executive committee will leave company in 2015

Three members of Novartis’ executive committee will leave company in 2015

09-10-2014

Swiss drug major Novartis has announced that three members of its executive committee will leave the…

BoardroomEli LillyGlaxoSmithKlineNovartisPharmaceuticalSwitzerland

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Eli Lilly's Humalog KwikPen approved in Europe for new 200 units/ml version

Eli Lilly's Humalog KwikPen approved in Europe for new 200 units/ml version

03-10-2014

US drug major Eli Lilly has received marketing authorization from the European Commission for its Humalog…

DiabetesEli LillyEuropeHumalogPharmaceuticalRegulation

1 to 25 of 204 results

COMPANY SPOTLIGHT

Menarini

Back to top